Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Kinex Pharmaceuticals announced today the successful completion of an oversubscribed private placement of equity which was limited to strategic...
Kinex Pharmaceuticals and Hanmi Pharmaceutical Co., Ltd. are pleased to announce the execution of an agreement for Kinex Pharmaceuticals to lead the...
Kinex Pharmaceuticals today announces the exclusive licensing of global rights of three patents from The Hong Kong Polytechnic University and McGill...
Kinex Pharmaceuticals announced today that the first actinic keratosis patient has been dosed with KX2-391 ointment in Austin, Texas. KX2-391 (KX01), ...
Kinex Pharmaceuticals announced today that Mr. Flint Besecker has been appointed Chief Operating Officer of the company. Mr. Besecker will have...
Hanmi Pharmaceuticals and Collaborative Partner Kinex Pharmaceuticals announce today preliminary results from a Phase I Clinical Study of Oratecan -...
Kinex Pharmaceuticals Inc. today announced that it has completed the acquisition of QuaDPharma, LLC., a Western New York based privately-held company ...
Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I...
Kinex Pharmaceuticals announced today that Dr. Jean-Pierre Sommadossi has elected to step down from the Board of Directors of Kinex but will continue ...
Kinex Pharmaceuticals announces the addition of two key executives to its clinical leadership team reporting to Chief Medical Officer, Dr. Rudolf...
Kinex Pharmaceuticals announced today to having received regulatory and ethics approvals to initiate the first clinical study of an oral form of...
Kinex Pharmaceuticals announced today the successful completion of an oversubscribed USD $40 million private placement of equity which was completed...
Kinex Pharmaceuticals and PharmaEssentia Corporation (Taiwan) announced today the execution of a new licensing agreement granting PharmaEssentia...
Kinex Pharmaceuticals, (Kinex), a leading specialty biotech focused on the development and commercialization of next generation oral therapies for...
Kinex Pharmaceuticals announced today that they have received Orphan Drug designation for KX02 for the treatment of gliomas, which are the most...
Kinex Pharmaceuticals today announced that the first patient has been dosed in its Phase Ib Oraxol study. Oraxol allows for oral delivery of...
Kinex Pharmaceuticals, a leading specialty biotech focused on the development and commercialization of next generation oral therapies for cancer and...
Kinex Pharmaceuticals is pleased to announce that Dr. David Hangauer has formally accepted a full time role with the company as its Chief Science...
Kinex Pharmaceuticals is pleased to announce that their application for the Small Entrepreneur Research Assistance Programme has been approved by the ...
Kinex Pharmaceuticals, Inc. announced today that the FDA has allowed its Investigational New Drug (IND) application for Oraxol. Oraxol allows for...
Kinex Pharmaceuticals and Hanmi Pharmaceutical Co., Ltd. are pleased to announce the execution of an agreement for Kinex Pharmaceuticals to lead...
Kinex Pharmaceuticals (Kinex), a leading specialty biotech focused on the development and commercialization of next generation oral therapies for...
Kinex Pharmaceuticals and Zenith Technology Corporation, through its affiliate ZenRx, announced today the execution of a collaborative licensing...
Kinex Pharmaceuticals announced that Dr. David Hangauer, co-founder and Chief Scientific Officer of Kinex, has been named the American Cancer...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.